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Overline: Prion Diseases
Single Sentence Summary: A sensitive blood diagnostic assay can identify patients with variant Creutzfeldt-Jacob disease before symptoms appear and during the clinical phase.

Abstract 
Variant Creutzfeldt-Jakob disease (vCJD) is a human prion disease resulting from the consumption of meat products contaminated by the agent causing bovine spongiform encephalopathy. Evidence supporting the presence of a population of silent carriers potentially able to transmit the disease through blood transfusion is increasing. The development of a blood-screening assay for both symptomatic vCJD patients and asymptomatic carriers is urgently required. Here we show that a diagnostic assay combining plasminogen-bead capture and protein misfolding cyclic amplification technologies consistently detects minute amounts of abnormal prion protein from French and British vCJD cases in the required femtomolar range. This assay allowed the blinded identification of 18 patients with clinical vCJD among 256 plasma samples from the two most affected countries, with 100% sensitivity (95% confidence interval [CI], 81.5 to 100%), 99.2% analytical specificity (95% CI, 95.9 to 100%) and 100% diagnostic specificity (95% CI, 96.5 to 100%). Interestingly, this assay also allowed the detection of silent carriage of prions 1.3 and 2.6 years before clinical onset in two blood donors who later developed vCJD. Our assay also demonstrates the presence of abnormal prion proteins in the blood of pre-symptomatic patients thus enabling assessment of the risk of vCJD transmission through blood transfusion. 


Introduction
Variant Creutzfeldt–Jakob disease (vCJD) was identified in 1996 in the United Kingdom (UK) as a zoonotic infection caused by the dietary transmission of Bovine Spongiform Encephalopathy (BSE)  ADDIN EN.CITE (, ). vCJD is a rare transmissible spongiform encephalopathy (TSE) with a long incubation period and with no validated test to identify affected individuals prior to clinical onset. Until recently, all clinical cases of vCJD evaluated for the prion protein gene (PRNP) were homozygous for methionine at codon 129 (59% of the Caucasian population)  ADDIN EN.CITE () with no cases in the alternative genotypes. The first confirmed vCJD clinical case in a patient heterozygous for methionine/valine has just been reported in the UK (). Patients with vCJD display an accumulation of abnormally folded prion protein (PrPTSE) in the brain and lymphoid tissues including the spleen, lymph nodes, appendix, and tonsils  ADDIN EN.CITE (, ) raising concerns about the risk of blood-borne infection. Indeed, the secondary transmission of prions through blood has been demonstrated in several animal models  ADDIN EN.CITE (). In the UK, four cases of infection by the vCJD agent have been reported in recipients of non–leukodepleted red-blood-cell concentrate from donors who were carriers for vCJD  ADDIN EN.CITE (). A fifth probable case was reported in a patient with hemophilia treated with coagulation Factor VIII manufactured from plasma derived from UK donors  ADDIN EN.CITE (). Infectivity in blood is thought to be split about equally between leukocytes and plasma, with negligible amounts directly associated with red blood cells or platelets (). Whereas clinical cases of vCJD are declining worldwide, the prevalence of asymptomatic carriers in the general population remains a concern. Investigations into the prevalence of asymptomatic carriers, using immunohistochemical detection of PrPTSE in a large series of appendix specimens, indicated an unexpectedly high rate of infection (1/2 000) in the general UK population  ADDIN EN.CITE (, ), which can be extrapolated to a prevalence of 1/20 000 in France where the level of exposure is considered to be ten times lower. Detecting circulating agents in asymptomatic subjects with peripheral prion infection is thus important for public health, in particular to avoid secondary transmission through blood transfusion. A prototype ELISA test was recently reported to identify vCJD cases by probing whole blood  ADDIN EN.CITE (). Several other strategies are being explored using blood  ADDIN EN.CITE () and urine from vCJD patients  ADDIN EN.CITE (). However, most blood tests have only reached around 70% sensitivity in blinded studies, thus falling short of the acceptance criteria of 90% required by the European Union (EU) Commission Directive 2011/100/EU for licensing for human use (). In addition, none of these tests have proven effective for detecting pre-symptomatic patients. We have previously described a blood diagnostic assay based on serial prion amplification by protein misfolding cyclic amplification (PMCA) (). To circumvent the presence of blood associated conversion inhibitors, we first captured the prion protein using magnetic nanobeads coated with plasminogen. Plasminogen was identified as a ligand of abnormal prion proteins using specific interactions with lysine residues by Fisher et al. (). Of particular interest is the capacity of plasminogen to bind to PrPTSE from various species including humans as well as sporadic CJD prions (). Plasminogen has also demonstrated the ability to stimulate prion conversion in vitro (). 
In our PMCA-based assay (), the capture step enables the concentration of prion proteins present in 500µl of plasma and their separation from blood-associated conversion inhibitors. Our assay has already achieved the level of performance required to detect PrPTSE at the femtomolar range () in plasma, buffy-coat or whole blood samples using either citrate or EDTA as anticoagulant. Here, by testing rare specimens from UK and French CJD surveillance centers, we further assess the performance of our assay against the strict requirements outlined in the amended Decision 2002/364/EC of the European Directive 98/79/EC () regarding the common technical specifications for vCJD blood screening assays. Our assay allowed us to diagnose in a blinded fashion the presence of PrPTSE in samples from 18 out of 18 symptomatic vCJD cases among a large sample collection including samples from patients with sporadic CJD (sCJD), with 100% sensitivity. It also permitted PrPTSE detection in plasma samples collected 14 and 31 months before clinical onset in two French blood donors who later developed vCJD.

Results 
Analytical sensitivity of the vCJD diagnostic assay
Our vCJD diagnostic assay consisted of a plasminogen-bead capture step followed by serial protein misfolding cyclic amplification (PMCA) (Fig. 1). We validated our vCJD assay for analytical sensitivity (test detection threshold) using a blinded reference panel consisting of plasma (in citrate anticoagulant) spiked with WHO reference materials from the National Institute for Biological Standards and Control (NHBY0/0003 for brain and NHSY0/0009 for spleen from vCJD patients) (). In order to refine these sensitivity data, we prepared an additional panel of human plasma samples spiked with serial dilutions of the same vCJD WHO reference brain tissue ranging from 10-5 to 10-12. After three PMCA rounds of 80 cycles, PrPTSE could be detected at a dilution of 10-9 (Fig. 2). Additional rounds of PMCA did not increase this level of analytical sensitivity. The number of misfolded PrPTSE molecules in the 10-10 dilution of the brain (and lower dilutions) and recovered by the plasminogen beads as the PMCA seed input, was likely insufficient to initiate the amplification process. However, this 10-9 dilution of analytical sensitivity is 4-5 log higher than the acceptance criteria of 10-4 dilution required by the Common Technical Specifications defined in the European Commission Directive regarding the performances of vCJD screening assays ().

Diagnostic sensitivity, analytical and diagnostic specificities of the vCJD assay
To evaluate the diagnostic sensitivity and the analytical specificity of our assay, we analyzed in a blinded fashion a total of 152 plasma samples from French and British patients, including 18 patients with vCJD, 67 with sCJD and 67 with non-CJD neurological diseases. In addition, plasma samples from 104 blood donors were tested as healthy controls to evaluate diagnostic specificity (Table 1).
Among the 152 plasma samples from patients, our assay blindly identified all 18 cases of clinical vCJD, thus achieving a diagnostic sensitivity of 100% (95% confidence interval [CI], 81.5 - 100). As shown in Table 2, of the 18 vCJD samples, one was positive after two rounds of PMCA, eight were positive after three rounds of PMCA and nine after four rounds. Whereas the detection limit was reached after 3 rounds of PMCA for brain material spiked into plasma (exogenous prions), one additional round of PMCA increased the sensitivity of the assay when plasma samples from vCJD patients (endogenous prions) were tested. Blood samples were obtained for all patients shortly before death, except for five that were collected at earlier clinical phases of the disease. The number of rounds required to obtain a positive signal showed no correlation with the time at which the tested sample was collected before the patient's death.
As shown in Table 1, our assay also showed high analytical specificity, with only one out of 134 potentially cross-reacting blood specimens from patients with sCJD, Alzheimer's disease, Parkinson's disease and other neurological diseases giving a positive result (99.2% specificity; 95% CI, 95.9 – 100). The positive specimen was from a 65 year-old patient with sCJD (type MM2a) from the UK. Two other plasma samples from type MM2a sCJD patients were tested in this study and gave negative results for PrPTSE. Results obtained on the whole UK panel (20 plasma samples) are shown in Figure 3. Representative results obtained on French plasma samples are shown in Figure 4A. No PrPTSE signal was detected in the 104 plasma samples from blood donors (Table 1) even after five rounds of PMCA, thus indicating a diagnostic specificity of 100% (95% CI, 96.5 – 100).
We then compared by western blot the PrPTSE molecular signature obtained for the clinical vCJD amplified samples with that of the reference brain samples from patients with sporadic or variant CJD (Fig. 3 and 4B). Samples from all of the vCJD patients displayed the characteristic type 2 mobility (19 kD) and clear predominance of the diglycosylated isoform (27 kD), whether amplified from plasma (Fig. 4B vCJD plasma) or from crude brain tissue (Fig. 4B vCJD BH). A similar type 2 mobility was also seen on the amplified products obtained from the UK patient samples (Fig. 3) including the 10 vCJD samples and strikingly with the sCJD patient classified as MM2a (UK 14 in Fig.3).

Preclinical detection of abnormal prions in plasma 
In France, since 1999, as an additional control for blood safety, two 500 µL non-leukodepleted aliquots of the plasma of all blood donations are archived in liquid nitrogen for 5 years by the Etablissement Français du Sang (French blood service). Three out of the 27 patients who developed clinical signs of vCJD had been regular blood donors (cases 8, 9 and 13). Eleven sequential archived plasma vials from two of these three donors were traced and specifically archived for long-term conservation. These vials correspond to the 7 last blood donations from donor A (case 8) and the 4 last donations from donor B (case 13). No archived samples could be traced for case 9. Donor A and B donated once or twice a year before they developed clinical signs of vCJD 7 and 2 months, respectively, after their last blood donation. Thus, we analyzed 11 non-leukodepleted plasma samples from donors A and B starting from 55 months and 30 months, respectively, before clinical symptom onset. For donor A (Fig. 5A), while the first 4 plasma samples (A1 to A4) were negative after 6 successive rounds of PMCA, we detected PrPTSE 31 months before clinical onset (A5) and in subsequent blood donations (A6 and A7) after 3 or 4 PMCA rounds. In donor B, after 6 PMCA rounds, PrPTSE detection was negative 30 months before clinical onset (B1) and became positive 14 months later (B2), which was 16 months prior to the appearance of clinical signs of the disease (Fig. 5B). Subsequent blood donations (B3 and B4) were also positive for vCJD prions after 3 or 4 PMCA rounds. These results demonstrate the presence of PrPTSE in the plasma of individuals during the presymptomatic phase of vCJD.

Discussion 
Here, we report a detection method in plasma allowing the diagnosis of clinical vCJD with 100% sensitivity, 99.2% analytical specificity and 100% diagnostic specificity. Despite the rarity of the samples, we have tested 18 blood samples from vCJD patients from France and the UK. Eighteen out of 18 clinical vCJD cases were identified in a blinded fashion. Such results satisfy the requirements for both sensitivity and specificity mandated by the European Commission Directive (). The finding that one out of 67 sCJD patients tested positive for PrPTSE in plasma may suggest that our assay could sporadically amplify type MM2a PrPTSE under conditions optimized for vCJD detection. The presence of infectivity in the blood of patients with sCJD has recently been reported (), but requires further investigation. Jackson et al.  ADDIN EN.CITE (), when determining the diagnostic performance of their prototype vCJD ELISA blood test, also found two patients with sCJD who tested positive, indicating some reactivity of their assay for sCJD in whole blood. Lastly, and as suggested by the results obtained in prevalence studies on appendix tissue  ADDIN EN.CITE (), we cannot exclude the possibility that the MM2a UK sCJD patient testing positive in our assay was also a carrier of vCJD infection in lymphoid tissue. No peripheral tissues are available from this case to investigate this hypothesis.
Using recombinant PrP as a substrate instead of brain homogenate and intensive agitation instead of sonication, real-time quaking induced conversion (RT-QuIC) has emerged as a powerful method for prion detection  ADDIN EN.CITE (, ). Independent studies have shown that the detection in the CSF or in the olfactory epithelium of PrPTSE for the diagnosis of sCJD by RT-QuIC may be 99 to 100% specific  ADDIN EN.CITE (). However, as yet, RT-QuIC appears to be less efficient in detecting PrPTSE from vCJD patients using various full-length recombinant PrP  ADDIN EN.CITE (), although the use of hamster-sheep chimeric PrP may improve its sensitivity (). From a clinical point of view, to date, RT-QuIC derived methods have not been used to diagnose vCJD. Two detection assays have been described for the detection of vCJD prions in blood with sensitivities close to 70%. The first one combines a solid-state binding matrix to capture and concentrate PrPTSE from whole blood samples with direct immuno-detection  ADDIN EN.CITE (). Having demonstrated 98.1% analytical specificity (95%CI 93.3-99.8%) with two sCJD positives detected and 100% diagnostic specificity (95%CI 99.9-100%) in 5000 US blood donor samples  ADDIN EN.CITE (), this assay appears promising as a screening assay. The second assay is a PMCA-based assay that has allowed the detection of PrPTSE in white blood cells from 3 out of 4 patients with clinical vCJD  ADDIN EN.CITE (). The diagnosis of vCJD may also be achieved using urine samples according to a third PMCA-based assay  ADDIN EN.CITE () which has also shown promising results: 92.9% sensitivity on 14 symptomatic vCJD patient samples (95%CI 66.1-99.8%) and 100% diagnostic specificity on 52 healthy control samples (95%CI 93.2-100%). There is no evidence that these assays are able to detect PrPTSE in carriers incubating the disease, who have not yet shown clinical symptoms.
Here, we report identification of asymptomatic patients with detectable PrPTSE in the blood before clinical onset. The observed kinetics of the appearance of detectable PrPTSE in plasma indicates that a pre-symptomatic diagnosis is possible up to 31 months before the first clinical symptoms appear. This is consistent with the intervals of 17 to 40 months between the blood donations most likely responsible for secondary vCJD transmission in the UK and the onset of vCJD symptoms observed in the corresponding donors  ADDIN EN.CITE (, , ). The number of PMCA rounds required to obtain a positive signal varied between 3 and 4 during the incubation period in each asymptomatic case and between 2 and 4 after clinical onset. The kinetics of circulating PrPTSE during the incubation period and during the clinical phase of the natural disease is unknown in humans. It remains unclear whether circulating PrPTSE continuously increases during the incubation period and whether it reaches a steady state during the clinical phase. It is worth noting that the presence of PrPTSE can be scarce in the lymphoid tissues of some symptomatic vCJD patients leading to false negatives on tonsil biopsy  ADDIN EN.CITE (, ). Our results suggest that circulating PrPTSE during incubation and disease usually fluctuates within the limits of detection corresponding to 3 or 4 rounds of our PMCA assay, that is, between 2 and 20 pg equivalent vCJD brain. A quantitative PMCA assay as described by Chen et al. () may be a useful approach to precisely assess PrPTSE concentrations in the blood of vCJD patients.
Our findings demonstrate that measurable amounts of PrPTSE with seeding activity can be found in the blood of humans at a pre-symptomatic stage. This has profound implications for public health and risk management, particularly in transfusion medicine. Our results provide a first estimation of the level of circulating abnormal prions in the plasma of patients in the final months of the incubation period for vCJD, which is not dissimilar from that observed in symptomatic patients. In France, no case of transfusion-transmitted vCJD has been reported so far in patients treated with blood products from the three vCJD patients who donated prior to symptom onset. This observation suggests that the precautionary measures introduced in France to safeguard blood transfusion, in particular leukodepletion, may have reduced the risk of transmission. With a limit of detection in the femtomolar range, our assay should allow a more precise evaluation of the residual risk of vCJD prion distribution in the different blood components. It may also be well suited for use as a complementary confirmatory assay, ensuring that any positive results from high-throughput blood screening assays are indeed true positives.
From a clinical point of view, a diagnostic method with 100% sensitivity is of special interest for diagnosis in young patients showing clinical signs that do not fulfill the criteria of probable vCJD, or in older patients with atypical forms of rapidly progressive dementia ().
There are some limitations to our study. Only a limited number of blood samples from vCJD patients with clinical disease were tested, but the number of samples in this study nonetheless fulfilled the requirements of the European Commission Directive () as vCJD is a very rare disease. In addition, the number of 18 symptomatic vCJD patients is within the range of recent international studies in the field of vCJD diagnosis  ADDIN EN.CITE (, ). Our study demonstrated the presence of PrPTSE in the plasma in only two pre-symptomatic vCJD cases, but samples of such pre-symptomatic blood donors are rare and their inclusion provided a unique opportunity to assess the kinetics of PrPTSE presence in blood during the incubation period. Until recently, all patients with clinical vCJD worldwide, including those enrolled in the present study (Table S1), have been methionine homozygous at codon 129 of the PRNP gene. The potential for infection to occur in lymphoid tissues and the central nervous system in the other genotypes at codon 129 is supported by the observation of PrPTSE accumulation in the lymphoid tissues of an asymptomatic heterozygous recipient of a potentially contaminated blood transfusion () and the recent report of the first vCJD case in a heterozygous patient (). In addition, 50% of the asymptomatic carriers identified in the prevalence study on appendix tissues  ADDIN EN.CITE () were not homozygous for methionine at codon 129. While the present study is an important first step for the systematic detection of infected individuals, with a significant potential impact on transfusion safety, whether the assay could detect PrPTSE in the blood of vCJD patients with other genotypes has yet to be confirmed.
In conclusion, our results provide valuable data on circulating abnormal prion proteins during the incubation phase in humans, and validate a new protein misfolding amplification-based assay that will reduce the potential risk of vCJD secondary transmission. Moreover, beyond these public health issues, our study provides evidence that a brain proteinopathy responsible for neurodegenerative disease can be diagnosed in asymptomatic patients through the detection of circulating abnormal protein aggregates. This finding is of interest for future translational research in neurological diseases caused by protein misfolding and aggregation, such as Alzheimer’s disease and Parkinson’s disease, for which there is a major need for a non-invasive early diagnostic test.




Materials and Methods
Study design
The aim of the study was to investigate the suitability of our blood diagnostic assay comprising plasminogen-bead capture coupled with protein misfolding cyclic amplification (PMCA) to identify vCJD-infected individuals. Compared with the handling of an emerging viral infection, development of a screening assay for infectious prions that in addition can be applied to blood samples from asymptomatic patients is challenging. In particular, only a small number of blood samples are available from clinical cases in France; no sero-conversion panels are available nor a gold standard assay against which candidate screening assays can be compared. From a regulatory point of view, vCJD assays for blood screening, diagnosis and confirmation have been added to List A of Annexe II to Directive 98/79/EC by Commission Directive 2011/100/EU the EU In Vitro Diagnostics Directive (IVDD), meaning that candidate assays must meet strict requirements with regard to sensitivity and specificity (). Our study aimed to meet these acceptance criteria by testing plasma samples distributed in blinded panels from the UK and France. These panels included 18 plasma samples from vCJD patients, 134 potentially cross-reacting plasma samples from patients with neurological disorders and 104 plasma samples from French blood donors. The detectability of PrPTSE in the blood of pre-symptomatic carriers was also assessed on 11 archived plasma vials from two blood donors who subsequently developed vCJD.

Normal plasma samples and reference brain tissues
To assess the diagnostic specificity, anonymized blood samples were collected from consenting French blood donors in compliance with French regulations (code de la santé publique article L.1243-3). Whole blood samples (n=104) were collected in EDTA-containing tubes. Plasma was isolated after centrifugation at 1500 x g for 15 minutes at 21°C and stored at -80°C until use.
For the study of analytical sensitivity, WHO reference brain samples (10% weight:volume) were provided by the National Institute for Biological Standards and Control (NIBSC, United Kingdom) under the reference number NHBY0/0003 for vCJD and number NHBX0/0001 for sCJD (methionine homozygous at codon 129 with PrPTSE type 1+2 [MM1+2]). Two additional sCJD brain samples were provided by CHU-Lyon (France) including one methionine homozygous case with PrPTSE type 1 (MM1) and one valine homozygous case with PrPTSE type 2 (VV2). NIBSC also provided a negative control WHO reference brain homogenate (number NHBZ0/0005).

Blind panels from the French CJD Surveillance Network
Since 1993, all CJD suspects across France have been notified to the national CJD surveillance network  ADDIN EN.CITE (). Most suspects are notified by the laboratories that perform cerebrospinal fluid examination for detection of the 14-3-3 protein. Other sources of notification are neurological clinics, neuropathology laboratories and the French national institute for public health surveillance, which collects data on all notifiable diseases. For each suspected case, the CJD surveillance network collects all available medical data to classify each case as sporadic, genetic, iatrogenic or variant CJD (definite, probable or possible), or non-CJD, using internationally recognized criteria  ADDIN EN.CITE (, ). Only definite and probable CJD cases are reported to the EuroCJD network and all vCJD cases to the European Centre for Disease Prevention and Control.
Blood sampling from cases with a suspected diagnosis of CJD notified to the surveillance network was initiated in June 2006. This collection is dedicated to the assessment of novel diagnostic procedures for CJD. An informed and signed consent from the patients or their relatives was obtained for each sample. The procedure was approved by the ethics committee of the Pitié-Salpêtriere hospital (CCPPRB/130-05). Blood was sampled in tubes containing sodium citrate, heparin, or EDTA. After centrifugation at 2000 x g for 15 minutes at 4°C, plasma, buffy coat, and red blood cells were sampled in aliquots of 150µL and stored at – 80°C. In this study, only EDTA plasma samples were used. Samples from 132 patients including 8 cases with vCJD (the last 8 cases on a total of the 27 French cases who have died of vCJD), 57 with sCJD and 67 with other neuropsychiatric diagnosis (see Table 1) were split up into 6 consecutive groups and provided blindly to undergo our testing procedure. 

Blind panels from the UK National CJD Research & Surveillance Unit
The NCJDRSU was established in 1990 and receives referrals of all suspect cases of CJD in the UK. Whenever possible, staff from the Unit visit the referred cases for assessment and collection of detailed medical data before classifying the cases using internationally recognized criteria  ADDIN EN.CITE (, ). Only definite and probable CJD cases are reported to the EuroCJD network and all vCJD cases to the European Centre for Disease Prevention and Control.
Blood samples have been obtained in all cases since 1990. Informed and signed consent were provided by the patient or relatives. The study was approved by the NHS Lothian Ethics Committee. The blood samples were collected in ETDA or citrate. After centrifugation at 400 x g for 10 minutes, plasma, buffy coat and red blood cells were stored at – 80°C. In this study samples stored in citrate or EDTA were used. In 8 vCJD samples the type of anticoagulant, either EDTA or citrate, was not recorded. Samples included 10 from vCJD cases (out of 178 cases of vCJD in the UK) and 10 from sCJD cases. The 20 samples were provided blinded to undergo the testing procedure.


Archived plasma panels from the Etablissement Français du Sang (French blood service)
Since 1999, two aliquots of non-leukodepleted plasma from all blood donations are archived for 5 years by the Etablissement Français du Sang (EFS) in liquid nitrogen in order to allow additional controls with regards to blood safety. These aliquots, each of 500 µL, are prepared from whole blood collected in EDTA-containing tubes. Eleven sequential archived plasma vials from two donors who later developed vCJD were traced and specifically archived for long-term conservation (over 5 years). These vials correspond to the last 7 blood donations for the 8th vCJD French case (Donor A) and the last four donations for the 13rd vCJD French case (Donor B). Nine archived plasma samples from blood donors who never developed CJD were added to this study.

Testing procedure
The testing procedure is a three-step assay () that captures PrPTSE from infected blood using plasminogen-coated magnetic nanobeads prior to serial amplification of PrPTSE via protein misfolding cyclic amplification (PMCA), and finally specific detection by western blot (Figure 1). Plasma samples were thawed in a water bath for 10 minutes at 37°C and clarified at 1500 x g for 5 minutes at 21°C. In the pre-analytical capture step, 10µL of 1% (weight:volume) beads (Ademtech, France) at 10µg plasminogen/mg of beads were added to a mix (1:1) of plasma samples (400 to 500µL) and ligation buffer (phosphate 0·1M, 0·5% sodium chloride, 0·1% sarkosyl, pH 7·4), before being incubated for 90 minutes at 25°C. After washing steps with phosphate-buffered saline, beads were directly resuspended in the PMCA substrate.
For the PMCA amplification, the source of PrP used as substrate was obtained from brain homogenates of healthy transgenic mice overexpressing 6 fold more human PrP with a methionine at codon 129 (Tg650 line) (). Brains were prepared at 10% (weight:volume) homogenate in converting buffer (phosphate-buffered saline containing 150mM sodium chloride and 1% Triton) and clarified at 2000 x g for 20 seconds before freezing at -80°C in single-experiment aliquots of PMCA substrate.
The captured prion protein was mixed with 90 µL of PMCA substrate in PCR-tubes containing three Teflon beads. Amplification (80 cycles) was performed by three different technicians using two different types of sonicators (S4000, Misonix and Q700, Qsonica). Each cycle is composed of an incubation step (29 minutes 40 seconds at 37°C) and a sonication step (20 seconds at 240W). Successive rounds of 80 cycles were performed by diluting the amplified material 1:10 in fresh PMCA substrate. To avoid any cross-contamination, experiments were carried out under strict quality controlled PCR conditions. In addition, positive samples were not systematically subjected to an additional PMCA round.
After amplification, protease-resistant prion protein was detected by western blot as previously described  ADDIN EN.CITE (). Samples were incubated with proteinase K (200 µg/mL) for 60 minutes at 45°C before denaturation at 100°C in denaturing buffer. Samples were run on 12% polyacrylamide gel electrophoresis, before being electro-transferred onto PVDF membrane and revealed using 3F4 or 12B2 monoclonal antibodies against prion protein.

Statistical analysis
Calculations of 95% Clopper-Person confidence intervals for sensitivities and specificities were performed according to the exact binomial test () using the free software R ().

 Supplementary Materials
Methods
Table S1. Codon 129 genotype of the patients included in this study (including pre-symptomatic cases).  ADDIN EN.CITE ()
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 for plasminogen-coated Nanobeads as a direct platform for cyclic amplification of the prion protein PrPSc.


Figure legends: 
Fig. 1. Assay for detecting PrPTSE in plasma samples from vCJD patients.
Clarified plasma (450µL) was mixed with 500µL of ligation buffer and 10µL of magnetic nanobeads coated with plasminogen. After incubation and washing steps, beads (as a pellet) were resuspended in PCR-tubes containing three Teflon beads and brain homogenate from healthy transgenic mice overexpressing human PrPC (tg650 line) as a source of normal prion protein for PrPTSE amplification. PMCA enabled an increase in the amount of PrPTSE by alternating incubation (29 minutes 40 seconds at 37°C) and sonication steps (20 seconds at 240W). After 80 cycles of PMCA, samples were analyzed by western blot and/or subjected to a subsequent round of PMCA by refreshing the substrate.

Fig. 2. Analytical sensitivity of the vCJD detection assay.
The analytical sensitivity of the assay was assessed by analyzing plasma samples supplemented with dilutions of vCJD reference brain tissue ranging from 10-5 to 10-12 ??. The PrPTSE signal was assessed by means of western blot analysis using the 3F4 antibody after proteinase K digestion. For each sample, 20µL of the product was loaded onto the gel. As a western blot control, a 10-3 dilution of the vCJD reference brain sample without any amplification (no PMCA) was plotted in each gel (-3na). The results obtained after each serial round of PMCA are shown. The asterisk indicates a faint signal from incomplete PrPC digestion. M, molecular-weight marker.
Fig. 3.  Detection of PrPTSE in plasma samples from UK patients with CJD.
Blinded plasma samples obtained from 20 UK CJD patients were analyzed. The PrPTSE signal was assessed by means of western blot analysis using 3F4 antibody after proteinase K digestion. For each positive signal, the equivalent of 7 to 10 µL of the product obtained after four rounds of PMCA were loaded onto the gel; whereas for negative signals, 20 µL of the product obtained after five rounds of PMCA were loaded onto the gel. UK-1, UK-2, UK-5, UK-6, UK-8, UK-11, UK-15, UK-16, UK-17 and UK-19 refer to vCJD patients. UK-3, UK-4, UK-7, UK-9, UK-10, UK-12, UL-13, UK-14, UK-18 and UK-20 refer to sCJD patients. NBH refers to a negative control brain homogenate from a non-CJD individual without any proteinase K digestion. M, molecular weight marker. The dotted line indicates blot splicing. 

Fig. 4. Detection of PrPTSE in plasma samples from French patients with vCJD. 
Blinded plasma samples obtained from 132 French patients (including the archived samples from the last 8 French cases with clinical vCJD) and 104 French blood donors as healthy controls (HC) were analyzed. The PrPTSE signal was assessed by means of western blot analysis using 3F4 antibody after proteinase K digestion. For each sample, 20µL of the product was loaded onto the gel. (A) Representative results obtained with the plasma from 2 vCJD patients and non-vCJD plasma samples. sCJD, sporadic CJD; vCJD, variant CJD; AD, Alzheimer's disease; PD, Parkinson's disease; -3na, western blot control (10-3 dilution of the vCJD reference brain without any amplification), TP 10-5, positive control of the amplification process (10-5 dilution of the vCJD reference brain sample after 80 cycles of PMCA); M, molecular-weight marker. The asterisk indicates a weak signal due to failure in sample loading. (B) Comparison of the PrPTSE molecular signatures obtained with plasma samples from 8 French vCJD clinical cases and that of the reference brain homogenates (BH). Shown is the relative immunoreactivity of 3F4 anti-PrP monoclonal antibody (epitope amino acids 109-112) and 12B2 anti-PrP monoclonal antibody (epitope amino acids 89-93). 12B2 is specific for type 1 PrPTSE as its epitope is cleaved during proteinase K digestion in type 2 PrPTSE. NBH refers to a negative control brain homogenate from a non-CJD plasma sample without any proteinase K digestion. M, molecular weight markers. The dotted line indicates blot splicing. 

Fig. 5.  Detection of PrPTSE in plasma from two blood donors in the preclinical phase of vCJD.
A set of 20 archived plasma vials stored at the Etablissement Français du Sang was tested. Seven plasma samples (labeled A1 to A7) had been collected from the 8th vCJD French case (Donor A) during each of his last blood donations before he developed clinical signs of disease. Similarly, 4 plasma samples (labeled B1 to B4) had been collected from the 13th vCJD French case (Donor B). Time of plasma sample collection (months) for each case is shown as are the dates at which the first clinical signs appeared. Nine plasma control samples were obtained from blood donors who never developed CJD. Results obtained for all the plasma samples from donor A (panel A) and donor B (panel B) and 6 control plasma samples (N1 to N6) are shown. The PrPTSE signal was assessed by means of western blot analysis with 3F4 antibody after proteinase K digestion. For each sample, 20µL of the product obtained after six rounds of PMCA was loaded onto the gel, except for samples labeled A5 – A6 – A7 –B2 – B3 – B4 for which the equivalent of 4µL of the product obtained after four rounds of PMCA was loaded. -3na, western blot control (10-3 dilution of the vCJD reference brain tissue without any amplification); NBH, a negative control brain homogenate from a non-CJD plasma sample without any proteinase K digestion; M, molecular weight markers. * indicates positive after 3 rounds;  # indicates positive after 4 rounds.



Table 1. Analytical performance of the plasminogen-based capture and amplification assay.

	Diagnosis	Patients with positive detection of PrTSE in plasma samples#/total #	Analytical performance% (95%CI)
clinicalCJD	Variant CJD 	18/18	Diagnostic sensitivity100%(81.5 - 100)
	Probable	4/4	
	Definite 	14/14	
	Sporadic CJD 	1/67	Analytical specificity99.2%(95.9 - 100)
	Probable	0/27	
	Definite 	1*/40	
non CJD	Other neurodegenerative diseases 	0/15	
	Alzheimer's disease	0/9	
	Lewy body dementia	0/3	
	Parkinson's disease	0/2	
	Frontotemporal dementia	0/1	
	Other non-neurodegenerative diseases 	0/52	
	Metabolic and toxic encephalopathies	0/14	
	Paraneoplastic encephalitis and cancer 	0/12	
	Neurovascular disease	0/7	
	Infectious diseases	0/6	
	Autoimmune encephalopathies	0/3	
	Other disorders**	0/10	
Blood donors	Healthy controls	0/104	Diagnostic specificity100%(96·5 - 100)
	Pre-symptomatic variant CJD***	2/2	

*UK patient aged 65 years, sCJD type MM2a
**Epilepsy (n=2), brain anoxia (n=2), psychiatric diseases (n=2), celiac disease (n=1), cerebellar ataxia (n=1), confusion (n=1), polyradiculoneuropathy (n=1)
*** Both patients are distinct from the eight French patients with clinical vCJD sampled during the clinical course of the disease


Table 2. Characteristics of the 18 vCJD clinical cases included in this study.
Case #	Duration of the clinical phase (months)	Time at which the tested sample was harvested(months before death)	Number of rounds of serial PMCA to detect PrPTSE in the plasma samples
FR-20	14.0	2.6	3
FR-21	8.7	2.8	3
FR-22	15.8	9.8	3
FR-23	9.8	1.9	4
FR-24	13.5	5.5	3
FR-25	13.4	5.5	3
FR-26	26.7	10.1	3
FR-27	27.1	21.2	4
UK-1	14	4.3	4
UK-2	15	10.5	3
UK-5	14	0.9	3
UK-6	10	3.4	4
UK-8	18	9.7	4
UK-11	18	6.0	4
UK-15	13	2.8	2
UK-16	24	0.4	4
UK-17	10	6.7	4
UK-19	15	2.0	4
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